Scleroderma Clinical Trial
Official title:
The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma
This study will evaluate the use of botulinum toxin for microstomia (also known as reduced oral aperture) in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase1-3. The study will include three arms: the temporomandibular joint (TMJ) group who will receive injections of Botox to the masseter, the perioral group who will receive injections of Botox around the lips, and a control group who will receive no treatment for ROA. Outcome measurements will include measurement of oral aperture size through measurement inter-labial distance and between the upper and lower lips and the inter-incisal distance, patient satisfaction via a Skindex16 survey, mouth disability via the Mouth Handicap in Systemic Sclerosis Scale (MHISS), and patient and physician satisfaction using the Visual Analogic Scale (VAS). The maximum number of subjects to be consented for this study is 30. The study is expected to last four months per subject from time of consent to last clinical evaluation. Conditions that may result in a subject exiting the study prior to completion date include non-compliance, withdrawal of consent, or safety concerns such as adverse events as a result of treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02798055 -
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
|
||
| Completed |
NCT01959815 -
Novel Screening Strategies for Scleroderma PAH
|
||
| Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
| Completed |
NCT02915835 -
Riociguat in Scleroderma Associated Digital Ulcers
|
Phase 2 | |
| Active, not recruiting |
NCT01895244 -
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT00930683 -
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
|
Phase 1 | |
| Completed |
NCT00883129 -
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
|
Phase 2 | |
| Completed |
NCT00074568 -
Scleroderma Registry
|
||
| Recruiting |
NCT04797286 -
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
|
Phase 2 | |
| Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT03207997 -
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
|
N/A | |
| Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
| Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A | |
| Completed |
NCT05080738 -
Upper Extremity Home Exercises in Patients With Scleroderma
|
N/A | |
| Recruiting |
NCT03726398 -
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
| Completed |
NCT02062125 -
Calcinosis in a Single-Center Scleroderma Population
|
||
| Completed |
NCT04588714 -
Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention
|
N/A | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT02835196 -
Optical Elastography of Systemic Sclerosis Skin
|